Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Next Previous
Search
Trial Profile

Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; Sabatolimab (Primary) ; Spartalizumab (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Urogenital cancer; Uveal neoplasms
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 20 Sep 2022 Status changed from active, no longer recruiting to discontinued due to business reasons.
    • 18 Sep 2022 This trial has been discontinued in Netherland, according European Clinical Trials Database record.
    • 15 Jul 2022 Planned End Date changed from 25 Jul 2022 to 29 Aug 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top